Inactive Instrument

Pluristem Therapeutics Inc. Nasdaq

Equities

US72940R1023

Biotechnology & Medical Research

Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results

June 14, 2018 at 07:01 am EDT

HAIFA, Israel, June 14, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, is delighted to announce that it has been invited by the Tel Aviv Stock Exchange (TASE) to open the weekly trading of the Israeli market, following the announcement of its positive study results.

Pluristem recently announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication, where treatment was found to reduce the incidence of revascularization, improve patients’ mobility and validate the design of the company’s ongoing multinational Phase III study in Critical Limb Ischemia.

The event will take place at the TASE on Sunday, June 17, 2018 at 9:30am Israel time.

Pluristem welcomes its partners, investors and friends to join the event.

Registration is required at: Investor.relations@pluristem.com.

Contact:

Karine Kleinhaus, MD, MPH
Divisional VP, North America
1-914-512-4109
karinek@pluristem.com

Efrat Kaduri
Head of Investor and Public Relations
972-74-7108600
efratk@pluristem.com

Primary Logo

Latest news about Pluristem Therapeutics Inc.

Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 08	MT
Sector Update: Health Care	Apr. 08	MT
Pluri Receives US Patent for Immune Cell Expansion	Apr. 08	MT
Pluri Inc. Unveils A Novel Method for Expansion of Immune Cells Using Proprietary Technology	Apr. 08	CI
Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing	Mar. 14	CI
Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation	Mar. 11	CI
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board	Mar. 06	CI
Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 12	CI
Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis	Jan. 23	CI
Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division	Jan. 08	CI
Pluri Inc. Launches New Business Division Offering Cell Therapy Manufacturing Services as Contract Development and Manufacturing Organization: PluriCDMO	Jan. 08	CI
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction	Dec. 21	CI
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 13	CI
Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-12	CI
Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation	23-08-16	CI
Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors	23-07-13	CI
Pluri Signs Contract With US Institute of Allergy and Infectious Diseases to Develop Radiation Syndrome Treatment	23-07-11	MT
Pluri Inc. Signs A Three Year $4.2 Million Contract with the U.S. National Institute of Allergy and Infectious Diseases	23-07-11	CI
Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-09	CI
Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-13	CI
Pluri Inc. announced that it has received $8.469323 million in funding	22-12-29	CI
Pluri Inc. announced that it expects to receive $8.170972 million in funding	22-12-12	CI
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-10	CI
Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-21	CI
Pluri Inc.(NasdaqGM:PLUR) dropped from S&P Global BMI Index	22-09-19	CI

Chart Pluristem Therapeutics Inc.

Duration

Period

More charts

Company Profile

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q3 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-1.82%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+2.56%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B

Other Biotechnology & Medical Research